306 results about "Depressed - symptom" patented technology

This disclosure relates to a method of treating depression and / or reducing risk of suicide, comprising administering a combination of about 90 mg to about 120 mg of bupropion hydrochloride, or a molar equivalent amount of another form of bupropion, and about 40 mg to about 50 mg of dextromethorphan hydrobromide, or a molar equivalent amount of another form of dextromethorphan. The combination may be administered twice a day to a human being suffering from major depressive disorder and having a score of 3 or greater on the Suicidality Item of the Montgomery-Åsberg Depression Rating Scale (MADRS-SI).

Provided herein are, inter alia, methods for identifying subjects suffering from depression that will respond to treatment with an antidepressant.

The present disclosure provides methods and dosing regimens for the treatment of depression (e.g., treatment resistant depression) with a mucoadhesive composition comprising N, N-dimethyltryptamine (DMT) or a pharmaceutically acceptable salt thereof.

The invention discloses a depression state detection system based on multiple modes, which belongs to the technical field of psychological counseling and comprises an information acquisition module, a preprocessing module, a feature extraction module, a depression state detection module and a depression state evaluation module. According to the method, questionnaire evaluation, semantic evaluation and mood emotion are combined, depression state evaluation of multi-modal information of the user is achieved, the depression state self-test threshold is lowered, and doctors can conveniently and comprehensively know the depression state of the patient. The depression self-evaluation scale is combined with the voice information under the stimulation task, so that the system can provide more accurate evaluation for the depression state of the user, and the accuracy and convenience of traditional depression state self-test are improved. The user self-detection design of the system improves the instantaneity and individuation of depression state detection, and the output depression state evaluation score can be used as an important basis for assisting a doctor in diagnosis and mastering the depression state change of a patient in real time.

The invention provides a teenager depression auxiliary diagnosis model training method and system based on multi-modal data, and relates to the technical field of mental health. According to the method, firstly, a VR intelligent interaction scene is constructed, and physiological data of juvenile depression and physiological data of a normal contrast subject in the VR intelligent interaction scene are synchronously collected; data preprocessing and feature extraction are conducted on the electroencephalogram data, the heart rate variability data and the eye movement data, a single-mode depression recognition model is obtained through classifier training, and then a multi-mode depression recognition model and a cross-mode depression recognition model are obtained. The teenager depression auxiliary diagnosis model obtained through machine learning is helpful for early discovery and timely treatment of teenager depression.

The invention relates to the technical field of artificial intelligence, and discloses an interpretable depression detection method and system, and the method comprises the steps: retrieving a post related to a depressive symptom from a user social media history; on the basis of the post text corresponding to the symptom problem, a problem perception text representation is generated through fusion of a Longform encoder and an attention mechanism, and an optimal reasoning strategy is selected from a predefined reasoning strategy pool through a hybrid expert network; based on an inference strategy of question perception text representation and selection, selecting a most adaptive large language model from a predefined large language model pool through a hybrid expert network; deducing the severity of each depression symptom of the user according to an inference strategy and a large language model, and calculating the overall depression symptom severity of the user; according to the method, the reasoning strategy and the large language model are dynamically selected through the hybrid expert network, the optimal processing combination is adaptively matched for different symptom features and post contents, and the limitation of a fixed reasoning mode is overcome.

The invention provides an intelligent diagnosis and treatment method and system for teenager depression based on large model collaboration, and the method comprises the steps: constructing a remote sensing human living microenvironment and growth soft environment data set, carrying out the preprocessing and feature extraction of the data set, carrying out the space-time matching and characterization of the environment and the brain-behavior clinical data of a subject individual, and carrying out the diagnosis and treatment of the teenager depression. Individual intervention queue data and feature representation matched with the environment are collected; establishing a knowledge graph based on a large model based on the acquired multi-dimensional data; and performing intelligent diagnosis and intervention of environment-brain-behavior enhancement based on the established knowledge graph. Based on a knowledge organization system of environment-brain-behavior auxiliary diagnosis, pathogenesis evaluation and individualized intervention, an environment-brain-behavior multi-dimensional knowledge graph oriented to adolescent depression diagnosis is constructed, and based on a large-model collaborative reasoning mechanism enhanced by environment-brain-behavior multi-dimensional knowledge, the adolescent depression diagnosis is more accurate. An intelligent and precise method system is provided for diagnosis and treatment of juvenile depression, and the diagnosis and treatment level is greatly improved.

The invention provides an application of a spleen T lymphocyte exosome in construction of a depression animal model, a stress rat spleen T lymphocyte exosome is injected into a mouse body to construct the depression animal model, and the depression animal model can be used for depression drug screening, drug efficacy evaluation or diagnosis, and can be used for treating depression. And the method can also be used for researching and revealing pathogenesis of depression. The invention also proves that the IL4 / IL4R alpha signal channel and the BDNF signal channel play an important role in depression through experiments. The invention has important significance for clinical research of depression.

The present disclosure relates to compositions comprising racemic ketamine, or a pharmaceutically acceptable salt thereof, for use in treating psychiatric disorders such as suicidality, suicidal ideation, major depressive disorder, treatment-resistant depression, and post-traumatic stress disorder.

Provided herein are, inter alia, methods for identifying subjects suffering from depression that will respond to treatment with an antidepressant.

The invention discloses a composition for treating depression and application of the composition. The composition for treating depression is prepared from the following components in parts by weight: 35 to 40 parts of ligustilide, 0.5 to 1.5 parts of atractydin and 0.1 to 1 part of alpha-cyperone. According to the invention, the active components in the Yueju pill, which are targeted to 5-HT1AR and 5-HTT, are compounded for the first time to prepare a new traditional Chinese medicine functional component composition, and in addition, the anti-depression effect of the active components is evaluated by establishing a reserpine mouse depression model, so that the anti-depression effect of the Yueju pill is improved. The result shows that the active component composition screened by the 5-HT1AR and 5-HTT targets can adjust the content of monoamine neurotransmitters in brain tissues in vivo to achieve the anti-depression effect, and in-vivo pharmacological experiments fully prove that the composition has the anti-depression effect.

The invention belongs to the technical field of medical application, and particularly relates to application of neomangiferin in preparation of an anti-depression drug, experiments find that the effect of neomangiferin is obviously better than that of mangiferin, although the neomangiferin and the mangiferin have the same main structure, the inventor finds that the effects of the neomangiferin and the mangiferin have obvious difference, and the effect of the neomangiferin and the mangiferin is obviously different. The compound is unexpected by the inventor before experiments, a new optional medicine is provided for research and development of anti-depression, and the effect of the anti-depression medicine is effectively improved.

The invention discloses a method for constructing a blood serum endogenous biomarker and a depression diagnosis model of a depression patient, which couples non-targeting and targeting screening technologies, systematically characterizes endogenous small molecule metabolites in blood serum, identifies differential metabolites between the depression patient and a healthy control group, and determines the blood serum endogenous biomarker and the depression diagnosis model of the depression patient. And then determining a biomarker closely related to depression by using a regression model. According to the invention, potential depression biomarkers such as N-methyl-L-alanine, N-acetylneuraminic acid, N-acetylglycine, thymine ribonucleoside, decanoyl carnitine, aspartic acid-phenylalanine and the like are discovered. The diagnosis model obtained by training according to the ratio of N-acetylglycine to thymine ribonucleoside has the highest accuracy (99%), and healthy and disease samples can be effectively distinguished by using a threshold value 2.434. Therefore, the ratio of N-acetylglycine to thymine ribonucleoside is a potential biomarker capable of realizing rapid and accurate diagnosis of depression.

The invention discloses application of a combination of probiotics GOLDGUT-M520 and GOLDGUT-LR99 in preparation of a product for relieving depression, and belongs to the technical field of biological medicines. The probiotics disclosed by the invention can be used for relieving depressive symptoms, improving related symptoms, assisting in treating depression and preventing depression, and also can be used as a nutritional supplement to help maintain the balance of intestinal microflora and promote intestinal health.

The present invention relates to Compound 1 for the use in the treatment of Major Depressive Disorder, Treatment-resistant Depression, Bipolar Depressive Disorder, Depressive Episodes associated with Bipolar disorders, Obsessive Compulsive Disorder, Post-Traumatic Stress Disorder, and / or Borderline Personality Disorder, chemical synthesis of Compound 1, polymorphs of Compound 1, and pharmaceutical compositions comprising Compound 1 and / or its polymorphs.

The invention provides a depressive disorder detection method and device based on sleep monitoring, and relates to the technical field of depression intelligent detection.The depressive disorder detection method comprises the steps that a polysomnogram of a to-be-detected object is obtained, and the polysomnogram comprises a plurality of physiological signals; inputting the plurality of physiological signals into a first depressive disorder detection model to obtain a first intermediate layer signal, the first depressive disorder detection model comprising an attention module, a CNN sequence, a first channel, and a data splicing module, the attention module is used for acquiring an attention index of each physiological signal, calculating an attention weight of each physiological signal and integrating all the attention weights into a second intermediate layer signal; inputting the first intermediate layer signal into a second depressive disorder detection model to obtain a third intermediate layer signal; and inputting the third intermediate layer signal into a third depressive disorder detection model to obtain a depressive disorder detection result of the to-be-detected object. According to the invention, the accuracy of the depressive disorder detection result is improved.

The invention discloses application of a mitochondrial differentiation expression gene in preparation of a depression diagnostic agent and a depression treatment drug, and relates to the technical field of depression diagnosis and treatment. And the mitochondrial differentiation expression gene comprises one or more of TFAM (Transforming Factor Amplification Molecular), SURF1 and NDUFB9. According to the present invention, the SURF1 gene simultaneously expressed in inhibitory neurons and excitatory neurons is focused on, the key effect of the SURF1 in CUMS-induced depression-like behaviors is found, the CUMS-induced molecular and behavior changes are effectively reversed by the overexpression of the SURF1, and the potential anti-depression effect is displayed; besides, animal experiments find that overexpression of the SURF1 can effectively recover the function of an electron transport chain, ATP generation is enhanced, mitochondrial membrane potential is maintained, and oxidative stress is reduced. The effects jointly relieve depression-like behaviors induced by CUMS, and further support the protection effect of the SURF1 in a depression model, which provides evidence for the new effect of the SURF1 in the pathophysiology of depression.

This disclosure relates to administration of a combination of: 1) about 100-110 mg, about 104-106 mg, or about 105 mg of bupropion hydrochloride, or a molar equivalent amount of a free base form or another salt form of bupropion; and 2) about 40-50 mg, about 44-46 mg, or about 45 mg of dextromethorphan hydrobromide, or a molar equivalent amount of a free base form or another salt form of dextromethorphan in certain patient populations, such as patients having moderate renal impairment, patients having mild or moderate hepatic impairment, patients receiving a concomitant strong CYP2D6 inhibitor, patients who are known CYP2D6 poor metabolizers, those in need of an NMDA antagonist that does not cause dissociation, and those at risk of QT prolongation.

To provide an AI system capable of estimating severity of dementia and / or depression in a subject on the basis of information obtained outside a hospital.SOLUTION: A method of creating teacher data for an AI system for estimating severity of dementia and / or depression is provided. Information to be used as teacher data for the AI system can be acquired from a site where a user receives prescribed drugs or from an application on a mobile terminal used by the user. The teacher data at least includes a face picture of the user, and a prescription, instruction, or information that enables estimation of dementia and / or depression in the user.SELECTED DRAWING: Figure 1

The invention relates to a co-crystal or salt comprising psilocin and a co-former. The co-crystal or salt is useful in methods of treating or preventing a disease or condition selected from depression, anxiety, death anxiety, demoralization, adjustment disorders, hopelessness, suicidal ideation, desire for hastened death, cocaine-related disorders, opioid-related disorders and stimulant-related disorders in a patient. A kit comprising the co-crystal or salt is also described.

To provide a compound useful for the treatment of mental disorders, such as a depressive condition including unipolar and bipolar depressive conditions, for example, but not limited to, depression, depression from generalized anxiety, major depression, treatment resistant depression, and postpartum depression.SOLUTION: The present invention provides a tryptamine prodrug compound represented by the following formula.SELECTED DRAWING: Figure 1

The invention relates to the technical field of depression drug development, and particularly discloses application of DACA in depression prevention and treatment drug development, the molecular formula of DACA is C24H30O6, DACA is applied to anti-depression activity, DACA is used as an active component to form a depression prevention and treatment drug together with a drug carrier, and the drug carrier is used as a drug carrier. The invention provides a new thought and approach for clinical prevention and treatment of depression, can be used for preparing medicines or health-care foods for preventing and treating depression, and has remarkable popularization and application values.

The invention discloses a related product of FT3 in depression risk assessment and application, and relates to the field of depression diagnosis. The marker provided by the invention comprises FT3 and shows a remarkable technical effect in the aspect of predicting depression, high-precision early recognition and risk prediction of depression are realized, a key window and an objective basis are provided for early active intervention and whole-course management of diseases, and the accuracy and reliability of screening and diagnosis are greatly improved. Meanwhile, the marker has excellent universality, is suitable for wide population screening, and lays a technical foundation for low-cost and high-efficiency large-scale depression screening. In conclusion, a brand new technical means is provided for effective diagnosis and risk early warning of depression, and the industrial application prospect is wide.

The present invention relates to a method for the differential diagnosis of bipolar versus unipolar disorder in a human patient during a depressive phase from a biological sample of the patient, comprising determining the relative proportions of RNA editing variants of at least the A-to-I-edited RNA ZNF267 gene. The present invention also relates to a method for monitoring the treatment of a depressed patient exhibiting bipolar or unipolar disorder. Finally, the present invention provides a kit for the differential diagnosis of bipolar versus unipolar disorder in a patient during a depressive phase.

This invention relates to the use of (4-benzylpiperazin-1-yl)-[2-(3-methylbutylamino)pyridin-3-yl]methanone (NSI-189) or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), bipolar disorder, post-traumatic stress disorder, substance use disorder, and depression-related aspects of schizophrenia (e.g. negative symptoms) in select patients who exhibit impaired learning and / or memory. The invention also relates to the use of NSI-189 or a pharmaceutically acceptable salt thereof in the treatment of a psychiatric condition in which depressive symptoms are prominent, including major depressive disorder (MDD), in select patients who exhibit impaired learning and / or memory or certain EEG characteristics.

An embodiment of the present invention provides a method for generating a depression diagnosis dialogue dataset. The method includes: initiating a dialogue with a real population including depression patients based on the clinical criteria for depression diagnosis to generate a patient portrait of the real population; simulating the depressive outpatient dialogue records between the patient role and the doctor role based on the patient portrait; supervising and filtering the depressive outpatient dialogue records to obtain a depression diagnosis dialogue dataset that meets the clinical criteria. The depression diagnosis dialogue dataset collected in the embodiments of the present invention is of great significance for studying the end-to-end depression consultation dialogue and symptom-based depression diagnosis. The dialogue system also plays a very important role in the large-scale screening and follow-up of depression, and can effectively help alleviate the problems caused by the imbalance of medical resources.

The disclosure provides methods for the acute treatment of depression and / or anxiety, for the enhancement of mTOR (e.g., mTORC1) signaling, and for the reduction of neuroinflammation, comprising administering to a patient in need thereof, a therapeutically effective amount of a 5-HT2A or 5-HT2A / D2 receptor ligand, e.g. lumateperone.

A method for treating a mental disorder in a subject, comprising the step of normalizing the expression of both DRD1 and DRD5 belonging to the DRD1-like family of the subject to a preset standard level. The DRD1 / 5 level and expression can be increased or decreased bidirectionally by targeting the upstream promoter sequence of DRD1 / 5. The promoter activity of DRD1 / 5 can be attenuated by using antipsychotic drugs that directly target the DRD1 / 5 promoter. The antipsychotic drugs used are typical and / or atypical antipsychotic drugs such as haloperidol, risperidone, clozapine, and cariprazine. This treatment is also useful for subjects in whom the constitutive expression of the DRD1 / 5 gene is impaired. This method can be used to treat schizophrenia, autism, depression, mania, and bipolar disorder by normalizing the DRD1 / 5 expression level. The promoter gene sequencing of DRD1 and / or DRD5 can also be used for quantitative mental health screening by comparing with a standard sequence database.

The present invention provides a method for constructing an emotion perception model and detecting the risk of early depression, which solves the problem that the emotion content and early description of depression symptoms expressed by users in social media are ignored in the existing methods, making it difficult to accurately judge whether the user is already in the early stage of depression. The present invention constructs a data set, obtains a social media dynamic data set of a user to be detected and obtains a set of early description posts of depression of the user to be detected containing at least one content; constructs the post representation layer, and uses a pre-trained language model to capture a context representation sequence that integrates negative emotion knowledge; constructs the user representation layer, and obtains a user representation matrix that integrates heterogeneous knowledge based on the output of the post representation layer; predicts the early depression risk level of the user to be detected through the detection layer; and obtains the emotion perception model after training, which can effectively detect and evaluate users with early depression.

The invention discloses application of micromolecule RNA in preparation of a medicine for treating depression, and belongs to the technical field of biomedicine. The invention finds that the small molecule RNA comprising the nucleotide sequence shown as ACAUUCA has a remarkable anti-depression effect. The micromolecule RNA, especially miR-181a-5p, acts on a chronic social contusion stress (CSDS) model mouse of which the expression level of the mPFC brain region is remarkably reduced, and the miR-181a-5p level of the mPFC brain region of the CSDS model mouse can be improved, so that the pathological change and depression-like behaviors of the CSDS mouse can be remarkably improved. According to the application of the small-molecule RNA in preparation of the anti-depression medicine, the small-molecule RNA can recover mitochondrial functions of neurons in a CSDS model mouse mPFC brain region, repair neuronal synaptic injury and improve and recover depression-like behaviors of depression diseases.